FSD Pharma Inc. | WebDisclosure

Basculer en Français

10926	Companies
238443	Keywords
167240	Articles
128094	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 5 months ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 5 months ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 5 months ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 5 months ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 5 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 5 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 5 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 6 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 6 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 6 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 09/03/2026 at 13:30, 6 minutes ago

Lyken.AI Enters Non-Binding MOU with FingerMotion and BlueFlare to Support Enterprise AI Infrastructure Strategy
Published on 09/03/2026 at 13:15, 21 minutes ago

Spirit Blockchain Capital Completes Previously Announced Shares for Services Issuance
Published on 09/03/2026 at 13:05, 31 minutes ago

Faraday Copper Reports Near-Surface Copper Mineralization in 14 Drill Holes, Increasing Confidence in Future Resource Growth
Published on 09/03/2026 at 13:00, 36 minutes ago

North Shore Intersects Significant Uranium Mineralization in All Phase 1 Drill Holes at Rio Puerco
Published on 09/03/2026 at 12:00, 1 hour 36 minutes ago

NuRAN Wireless Announces Creation of NuEnergy, a Solar, Storage and Hybrid Power Subsidiary

View all ACCESSWIRE

EQS Group

Published on 09/03/2026 at 13:05, 30 minutes ago

Datamaran Rebrands, Shifting from ESG Issue Management to Enterprise Governance
Published on 09/03/2026 at 13:05, 30 minutes ago

BARTEC Launches New Modular Energy Distribution Panel Series for Hazardous Areas
Published on 09/03/2026 at 13:00, 36 minutes ago

Dividend Declaration
Published on 09/03/2026 at 12:40, 56 minutes ago

DN Group Reports Solid First Half of 2026
Published on 09/03/2026 at 12:05, 1 hour 30 minutes ago

EXIN launches the AI Security Professional certification, built on the OWASP AI Exchange -- making AI security skills transparent and verifiable

Les Echos

Published on 09/03/2026 at 09:00, 4 hours 36 minutes ago

Transfert effectif des titres Gerard Perrier Industrie sur Euronext Growth Paris à compter du 7 septembre 2026
Published on 09/03/2026 at 07:00, 6 hours 36 minutes ago

Excellent portfolio performance leads to a 7.5% increase in Net Asset Value to EUR 57.2 per share
Published on 09/03/2026 at 07:00, 6 hours 36 minutes ago

Excellent portfolio performance leads to a 7.5% increase in Net Asset Value to EUR 57.2 per share
Published on 09/03/2026 at 07:00, 6 hours 36 minutes ago

Uitstekende portefeuilleprestaties leiden tot stijging van de intrinsieke waarde met 7,5% tot EUR 57,2 per aandeel
Published on 09/02/2026 at 21:30, 16 hours 6 minutes ago

Accor announces the success of OCEANEs due 2032 for a nominal amount of €380 million and the results of the partial repurchase of its outstanding OCEANEs due 2027

View all LES ECHOS COMFI WIRE